FZD8 and prostate carcinoma: To confirm the in silico data, immunohistochemistry for FZD8 and Wnt-11 was carried out in tissue arrays (TMAs) comprising sections of benign and malignant prostate from prostate cancer patients (Supplementary Table 5).